Stocktoria
BullFrog AI Holdings, Inc. BFRG
BullFrog AI Holdings, Inc. (BFRG) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $116,670 at a -5569.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
| SER | Serina Therapeutics, Inc. | 2/9 | — | — | — |
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
About BullFrog AI Holdings, Inc.
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
FAQ
Is BFRG financially healthy?
BullFrog AI Holdings, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does BFRG pay a dividend?
No, BullFrog AI Holdings, Inc. does not currently pay a dividend.
How profitable is BFRG?
In FY2025, BullFrog AI Holdings, Inc. had a net margin of -5569.6% and a return on equity of -304.2%.
Is BFRG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BullFrog AI Holdings, Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.